- Home
- FLNG vs ELVN Comparison
FLNG vs ELVN Comparison
Compare FLNG & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNG
- ELVN
- Stock Information
- Founded
- FLNG 2006
- ELVN 2016
- Country
- FLNG Bermuda
- ELVN United States
- Employees
- FLNG N/A
- ELVN N/A
- Industry
- FLNG Marine Transportation
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- FLNG Consumer Discretionary
- ELVN Health Care
- Exchange
- FLNG Nasdaq
- ELVN Nasdaq
- Market Cap
- FLNG 1.3B
- ELVN 1.2B
- IPO Year
- FLNG N/A
- ELVN 2020
- Fundamental
- Price
- FLNG $24.94
- ELVN $19.02
- Analyst Decision
- FLNG Hold
- ELVN Strong Buy
- Analyst Count
- FLNG 1
- ELVN 5
- Target Price
- FLNG $23.00
- ELVN $41.20
- AVG Volume (30 Days)
- FLNG 599.1K
- ELVN 489.5K
- Earning Date
- FLNG 11-11-2025
- ELVN 11-12-2025
- Dividend Yield
- FLNG 12.04%
- ELVN N/A
- EPS Growth
- FLNG N/A
- ELVN N/A
- EPS
- FLNG 1.83
- ELVN N/A
- Revenue
- FLNG $355,837,000.00
- ELVN N/A
- Revenue This Year
- FLNG N/A
- ELVN N/A
- Revenue Next Year
- FLNG $3.41
- ELVN $20.05
- P/E Ratio
- FLNG $13.54
- ELVN N/A
- Revenue Growth
- FLNG N/A
- ELVN N/A
- 52 Week Low
- FLNG $19.46
- ELVN $13.30
- 52 Week High
- FLNG $27.67
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- FLNG 41.83
- ELVN 44.06
- Support Level
- FLNG $24.65
- ELVN $18.01
- Resistance Level
- FLNG $25.90
- ELVN $20.30
- Average True Range (ATR)
- FLNG 0.58
- ELVN 1.11
- MACD
- FLNG -0.27
- ELVN -0.16
- Stochastic Oscillator
- FLNG 9.44
- ELVN 30.70
About FLNG FLEX LNG Ltd.
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The fleet consists of thirteen modern LNG ships, ten existing and three under construction for delivery. All LNG carriers are equipped with slow-speed, two-stroke engines MEGI or X-DF propulsion which will provide Charterers with tonnage offering advantages in form of reduced fuel consumption and lowered boil-off rates.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.